HUE046788T2 - Gyógyászati készítmény rák kezelésére és/vagy megelõzésére - Google Patents
Gyógyászati készítmény rák kezelésére és/vagy megelõzéséreInfo
- Publication number
- HUE046788T2 HUE046788T2 HUE13751159A HUE13751159A HUE046788T2 HU E046788 T2 HUE046788 T2 HU E046788T2 HU E13751159 A HUE13751159 A HU E13751159A HU E13751159 A HUE13751159 A HU E13751159A HU E046788 T2 HUE046788 T2 HU E046788T2
- Authority
- HU
- Hungary
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012035342 | 2012-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE046788T2 true HUE046788T2 (hu) | 2020-03-30 |
Family
ID=49005808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13751159A HUE046788T2 (hu) | 2012-02-21 | 2013-02-21 | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9260513B2 (enExample) |
| EP (1) | EP2818481B1 (enExample) |
| JP (1) | JP6187257B2 (enExample) |
| KR (1) | KR102005308B1 (enExample) |
| CN (1) | CN104114581B (enExample) |
| AU (1) | AU2013223137B2 (enExample) |
| BR (1) | BR112014021099A2 (enExample) |
| CA (1) | CA2864999C (enExample) |
| DK (1) | DK2818481T3 (enExample) |
| ES (1) | ES2749672T3 (enExample) |
| HU (1) | HUE046788T2 (enExample) |
| IN (1) | IN2014KN01714A (enExample) |
| MX (1) | MX363136B (enExample) |
| PL (1) | PL2818481T3 (enExample) |
| PT (1) | PT2818481T (enExample) |
| RU (1) | RU2639522C2 (enExample) |
| WO (1) | WO2013125630A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027332T2 (en) | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| CA2733223C (en) | 2008-08-05 | 2018-02-27 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers |
| WO2011096534A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN103718045B (zh) * | 2011-08-04 | 2016-08-17 | 东丽株式会社 | 胰癌的检测方法 |
| DK2740489T3 (en) * | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| BR112014021102A2 (pt) | 2012-02-21 | 2021-12-28 | Toray Industries | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| MX357965B (es) | 2012-03-30 | 2018-08-01 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. |
| PT2832365T (pt) * | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
| DK2876446T3 (en) | 2012-07-19 | 2019-03-11 | Toray Industries | Method for detecting cancer |
| JP6244912B2 (ja) | 2012-07-19 | 2017-12-13 | 東レ株式会社 | 癌の検出方法 |
| CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| EP3484518B1 (en) | 2016-07-07 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Antibody adjuvant conjugates |
| CA3041979A1 (en) | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20200136935A (ko) * | 2018-03-30 | 2020-12-08 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CA3142887A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| JP7709431B2 (ja) | 2019-10-25 | 2025-07-16 | ボルト バイオセラピューティクス、インコーポレーテッド | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
| CA3175127A1 (en) * | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4119160A4 (en) * | 2020-03-12 | 2024-04-03 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| CA3175137A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2021182572A1 (enExample) | 2020-03-12 | 2021-09-16 | ||
| WO2021182570A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| US20230293716A1 (en) | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| AU2021326516A1 (en) | 2020-08-13 | 2023-04-13 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| CA3225422A1 (en) | 2021-06-23 | 2022-12-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| BR112023026985A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agente que aumenta a eficácia do medicamento em uma composição farmacêutica, agente para aumentar a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
| MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| EP4378476A4 (en) | 2021-07-27 | 2025-07-23 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| MX2024001099A (es) | 2021-07-27 | 2024-02-23 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| US20250281630A1 (en) | 2021-09-03 | 2025-09-11 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| WO2024005123A1 (ja) | 2022-06-30 | 2024-01-04 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JPWO2024043252A1 (enExample) | 2022-08-24 | 2024-02-29 | ||
| JPWO2024043257A1 (enExample) | 2022-08-24 | 2024-02-29 | ||
| JPWO2024043258A1 (enExample) | 2022-08-24 | 2024-02-29 | ||
| WO2024048542A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN119789868A (zh) | 2022-08-30 | 2025-04-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| JPWO2024135809A1 (enExample) | 2022-12-23 | 2024-06-27 | ||
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2025058000A1 (ja) * | 2023-09-13 | 2025-03-20 | 東レ株式会社 | 癌の治療、予防及び／又は診断用医薬組成物 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| PT1069185E (pt) | 1998-04-03 | 2011-08-11 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| TW200728465A (en) | 1998-07-14 | 2007-08-01 | Corixa Corp | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| AU4185100A (en) | 1999-04-02 | 2000-10-23 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2388822A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| HUP0500345A2 (hu) | 2000-03-29 | 2005-07-28 | Corixa Corporation | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására |
| ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| CA2508763C (en) | 2001-05-11 | 2012-01-24 | Kirin Beer Kabushiki Kaisha | Human antibody producing mouse and method for producing human antibody using the same |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| EP1629119A2 (en) | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| MXPA06010715A (es) | 2004-03-19 | 2007-05-23 | Imclone Systems Inc | Anticuerpo del receptor del factor de crecimiento humano anti-epidermico. |
| NZ550225A (en) | 2004-03-30 | 2010-11-26 | Glaxo Group Ltd | Immunoglobulins that bind oncostatin and inhibit or block interaction between hOSM and pg130 |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
| WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| JP5069214B2 (ja) | 2005-03-11 | 2012-11-07 | ヴァーミリオン インコーポレイテッド | 卵巣癌及び子宮内膜癌のバイオマーカー：ヘプシジン |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| US8211634B2 (en) | 2006-02-14 | 2012-07-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| CN110251670B (zh) | 2008-03-18 | 2023-11-14 | 健泰科生物技术公司 | 抗her2抗体-药物偶联物和化疗剂的组合，及使用方法 |
| HUE027332T2 (en) * | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| BRPI0912462B1 (pt) | 2008-08-05 | 2022-03-22 | Toray Industries, Inc | Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante |
| CA2733223C (en) * | 2008-08-05 | 2018-02-27 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers |
| WO2011020529A2 (en) | 2009-08-19 | 2011-02-24 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| WO2011035884A1 (en) | 2009-09-22 | 2011-03-31 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| PT2532364T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica que compreende anticorpos anti caprin-1 para o tratamento e/ou a prevenção de cancro |
| JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2011096533A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2011096534A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| WO2012013609A1 (en) | 2010-07-26 | 2012-02-02 | Bioréalités S.A.S. | Methods and compositions for liver cancer therapy |
| JP5545105B2 (ja) | 2010-08-04 | 2014-07-09 | 株式会社ジェイテクト | トロイダル型無段変速機のディスクの研磨方法およびトロイダル無段変速機のディスクの研磨装置 |
| CN103718045B (zh) | 2011-08-04 | 2016-08-17 | 东丽株式会社 | 胰癌的检测方法 |
| DK2740489T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| MX357965B (es) | 2012-03-30 | 2018-08-01 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. |
| PT2832365T (pt) | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
-
2013
- 2013-02-21 EP EP13751159.8A patent/EP2818481B1/en active Active
- 2013-02-21 RU RU2014138039A patent/RU2639522C2/ru active
- 2013-02-21 JP JP2013512279A patent/JP6187257B2/ja active Active
- 2013-02-21 BR BR112014021099-3A patent/BR112014021099A2/pt not_active Application Discontinuation
- 2013-02-21 IN IN1714KON2014 patent/IN2014KN01714A/en unknown
- 2013-02-21 WO PCT/JP2013/054312 patent/WO2013125630A1/ja not_active Ceased
- 2013-02-21 CA CA2864999A patent/CA2864999C/en active Active
- 2013-02-21 PT PT137511598T patent/PT2818481T/pt unknown
- 2013-02-21 PL PL13751159T patent/PL2818481T3/pl unknown
- 2013-02-21 AU AU2013223137A patent/AU2013223137B2/en active Active
- 2013-02-21 ES ES13751159T patent/ES2749672T3/es active Active
- 2013-02-21 US US14/379,868 patent/US9260513B2/en active Active
- 2013-02-21 DK DK13751159.8T patent/DK2818481T3/da active
- 2013-02-21 HU HUE13751159A patent/HUE046788T2/hu unknown
- 2013-02-21 CN CN201380009166.3A patent/CN104114581B/zh active Active
- 2013-02-21 MX MX2014009747A patent/MX363136B/es unknown
- 2013-02-21 KR KR1020147020831A patent/KR102005308B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014KN01714A (enExample) | 2015-10-23 |
| US9260513B2 (en) | 2016-02-16 |
| MX2014009747A (es) | 2014-11-14 |
| DK2818481T3 (da) | 2019-10-14 |
| US20150044221A1 (en) | 2015-02-12 |
| ES2749672T3 (es) | 2020-03-23 |
| EP2818481A4 (en) | 2015-10-07 |
| WO2013125630A1 (ja) | 2013-08-29 |
| RU2014138039A (ru) | 2016-04-10 |
| EP2818481B1 (en) | 2019-08-07 |
| CA2864999C (en) | 2020-06-30 |
| KR20140130670A (ko) | 2014-11-11 |
| CN104114581A (zh) | 2014-10-22 |
| CA2864999A1 (en) | 2013-08-29 |
| PL2818481T3 (pl) | 2020-02-28 |
| EP2818481A1 (en) | 2014-12-31 |
| AU2013223137B2 (en) | 2017-10-19 |
| RU2639522C2 (ru) | 2017-12-21 |
| JP6187257B2 (ja) | 2017-08-30 |
| BR112014021099A2 (pt) | 2020-12-01 |
| PT2818481T (pt) | 2019-10-25 |
| JPWO2013125630A1 (ja) | 2015-07-30 |
| MX363136B (es) | 2019-03-12 |
| AU2013223137A1 (en) | 2014-09-11 |
| CN104114581B (zh) | 2018-11-30 |
| KR102005308B1 (ko) | 2019-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE046788T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| HUE036424T2 (hu) | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére | |
| HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
| PT3031826T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro | |
| PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| PL2740489T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740794T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów | |
| HUE044611T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| PT2824114T (pt) | Composição farmacêutica para o tratamento do cancro | |
| HUE040012T2 (hu) | Gyógyászati ágens rák kezelésére és/vagy megelõzésére | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
| IL225471B (en) | Preparations for the prevention and treatment of cancer | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| IL238126A0 (en) | Compositions for the treatment and prevention of obesity | |
| EP2902027A4 (en) | ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer |